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lowed by either autologous or allogeneic transplant. We report
modest TRM, high CR rates and favorable survival following
allogeneic transplants. Younger patients with responsive disease
undergoing early transplant may have a superior survival and lower
TRM. This group may be suitable candidates for allogeneic trans-
plant.
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gasia, M.1, Kassim, A.1, Mineshi, S.1, Morgan, D.S.1, Ruffner, K.1,
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Oncology, Vanderbilt University Medical Center and Veterans Admin-
istration Medical Center, Nashville, TN; 2. Department of Biostatistics,
Vanderbilt University Medical Center, Nashville, TN
Introduction: Histological transformation of low-grade follicu-
lar NHL to a higher grade occurs in greater than 50% of patients
during the course of their disease. Historically, prognosis of these
patients is poor following conventional chemotherapy with median
survival of less than a year. SCT following dose intensiﬁcation has
been shown in few studies to improve the survival in such patients.
Methods: We performed a retrospective review of the pathology
of 367 adult NHL patients who underwent high-dose chemother-
apy and SCT at our institution between 1992 and 2002. We
identiﬁed 34 patients with follicular low-grade NHL who had
transformed to intermediate grade disease (diffuse large cell or
transformed large cell-REAL grade III). Patients with transforma-
tion to high grade or immunoblastic NHL were excluded. Results:
Thirty-one patients underwent autologous and 3 underwent allo-
geneic SCT. Median age at transplant was 53 years (35-69). 70% of
patients were male. 26% (9/34) patients had transformed disease at
diagnosis (had concurrent low-grade histology) and 74% (25/34)
had transformation at ﬁrst relapse. The median time to transfor-
mation from low to intermediate grade was 930 days (630-5430
days). 85% of the patients had advanced disease (stage III-IV) at
transformation. Median number of treatments for transformed
disease prior to SCT was 2 (1-6). 24 patients were in a partial
remission (PR), 6 in a complete remission (CR) and 4 had stable
disease at time of SCT. 76% (26/34) patients received a non-TBI
based conditioning regimen; 85% received peripheral blood stem
cells with a median CD34 dose of 3.45  106/kg. All patients
showed normal engraftment. Survival at 100 days was 97%
(95%CI 91%-100%), the only peri-SCT death occurred in the
allogeneic group. Median overall survival (OS) from SCT was 48
months (95%CI 38 mo-not reached) and 4-year OS was 49%.
Median disease free survival (DFS) from SCT was 20 months
(95%CI of 10-57months) with a 4-year DFS of 18%. The number
of prior therapies and time to transformation had no impact on the
survival. Subgroup of patients with stable disease (no response to
chemotherapy) prior to SCT had the worst outcome. Conclusion:
Our survival data indicates that one-half of patients with trans-
formed NHL will survive 4 years and one third of the survivors will
be disease free. SCT should be considered for eligible patients with
chemosensitive histologically transformed NHL.
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TER NONMYELOABLATIVE CONDITIONING FOR PATIENTS WITH POOR
RISK, RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Georges, G.E.1, Maris, M.B.1, Sandmaier, B.M.1, Stuart, M.J.2, Nied-
erwieser, D.3, Agura, E.4, Bruno, B.5, McSweeney, P.6, Anasetti, C.1,
Storb, R.1, Maloney, D.G.1 1. Fred Hutchinson Cancer Research Center
and Univerisity of Washington, Seattle, WA; 2. Stanford University,
Palo Alto, CA; 3. University of Leipzig, Germany; 4. Baylor University,
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We investigated the feasibility of HLA-matched unrelated donor
(URD) hematopoietic cell transplantation (HCT) in patients with
advanced stage, poor-risk multiple myeloma after nonmyeloabla-
tive conditioning. Eighteen patients, median age 53 years (range,
29-66), were enrolled between 5/2000 and 12/2002. At study entry,
12 patients had relapsed/refractory disease after a preceding autol-
ogous HCT, 5 patients had refractory disease following multiple
standard chemotherapy regimens, and 1 patient achieved a partial
remission (PR) after standard chemotherapy. Nine patients under-
went a planned high dose autologous HCT (Melphalan 200 mg/
m2) a median of 75 days prior to URD HCT, including 4 of the 12
patients with relapsed/refractory disease after prior failed autolo-
gous HCT. Two of the 18 patients were in complete remission
(CR, IBMTR/ABMTR criteria) immediately prior to URD HCT.
Nonmyeloablative conditioning consisted of ﬂudarabine (30 mg/
m2  3 days) and 2 Gy total body irradiation. A median of 8.6 
106 CD34/kg G-CSF-stimulated peripheral blood mononuclear
cells were transplanted from URDs matched for HLA-A, -B, -C
antigens and -DRB1 and -DQB1 alleles. Postgrafting immunosup-
pression included mycophenolate mofetil and cyclosporine. Dura-
ble engraftment was achieved in 17 of 18 patients. Acute GVHD
occurred in 13 (72%) patients and was exclusively grades II and III
in 11 and 2 patients, respectively. Chronic extensive GVHD oc-
curred in 11/16 (69%) of evaluable patients. After allografting, 7
patients (39%) achieved CR and 3 (17%) achieved PR, for an
overall response rate of 56%. Three patients (17%) died of pro-
gressive disease and 4 patients (22%) died of non-relapse causes at
a median of 5 months after URD HCT. With a median follow-up
of 15 months after URD HCT, 11 of 18 patients (61%) were alive,
6 (33%) in CR, 2 (11%) in PR and 3 (17%) with stable disease
(SD). Of the 9 patients who underwent a planned high dose
autologous HCT followed by URD HCT, 7 were alive: 5 in CR,
1 in PR and 1 with SD. In summary, URD HCT after nonmy-
eloablative conditioning is feasible with a relatively low non-re-
lapse mortality and provides a high response rate for patients with
relapsed or refractory multiple myeloma. The data also suggest
that intensive cytoreductive therapy (autologous HCT) followed
by URD HCT may be an effective salvage approach for treating
patients with poor risk, chemotherapy refractory multiple my-
eloma or after failed prior autologous HCT.
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NO ADVANTAGE FOR MORE THAN 4 CYCLES OF VAD PRIOR TO AU-
TOLOGOUS STEM CELL TRANSPLANTATION FOR MULTIPLE MYELOMA
Rodriguez, C.P., Bolwell, B., Ronald, S., Pohlman, B., Rybicki, L.,
Kalaycio, M.E. Department of Hematology and Medical Oncology,
Cleveland Clinic Foundation, Cleveland, OH
Patients with myeloma are typically treated with several cycles of
infusional vincristine, doxorubicin and dexamethasone (VAD)
prior to autologous stem cell transplant. We reviewed our experi-
ence to determine if an optimal number of VAD cycles (Vincristine
0.4 mg/day IV days 1-4, Doxorubicin 9mg/m2/day IV days 1-4,
Dexamethasone 40mg PO days 1-4, 9-12, 17-20) could be identi-
ﬁed. The records of 95 patients who underwent autologous pe-
ripheral stem cell transplantation for multiple myeloma from 1989
to 2001 were reviewed. Data on each patient’s pretransplant che-
motherapy regimen, response to initial chemotherapy and toxicity
during transplantation were obtained. Seven patients who suffered
relapse after initial chemotherapy were excluded during the data
analysis. The Kaplan Meier method was used to estimate survival
in the remaining 88 patients. Of the 88 patients treated, 62 were
treated with VAD for a median of 4 cycles (range 1-9) before
transplant. Thirty six patients were treated with 4 cycles of VAD,
9 were treated with less than 4 cycles, 15 received more than 4
cycles and two received an unknown number of cycles. Fourteen
patients received VAD either before of after other chemotherapy
regimens. Of the 26 patients who were treated with regimens other
than VAD, most included melphalan. One patient received an
unknown type of chemotherapy. Patients had to demonstrate at
least a partial remission in order to proceed with transplantation.
Autologous stem cells were harvested after GCSF mobilization. All
patients were admitted to the hospital and were treated with Busul-
fan (1mg/kg every 6 hours for 16 doses, days 1 to 4) and Cyclo-
phosphamide (60 mg/kg daily for 2 doses). GCSF was given after
transplant in addition to other standard supportive care practices.
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